| Quarterly Financials | Jun 2018 | Sept 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sept 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sept 2020 | Dec 2020 | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 |
Revenue  | 890 | 1,027 | 1,020 | 895 | 1,099 | 1,299 | 1,231 | 1,088 | 1,547 | 1,377 | 1,425 | 1,135 | 1,587 | 1,563 | 1,443 | 1,304 | 1,608 | 1,637 | 1,577 | 1,548 | 1,630 | 2,073 | 2,144 | 2,052 | 2,113 | 2,381 | 2,266 |
| Expenses | 757 | 838 | 772 | 716 | 881 | 1,019 | 942 | 908 | 947 | 1,003 | 1,045 | 886 | 1,152 | 1,184 | 1,123 | 1,070 | 1,317 | 1,341 | 1,330 | 1,331 | 1,278 | 1,713 | 1,722 | 1,848 | 1,700 | 1,913 | 1,782 |
| EBITDA | 133 | 188 | 247 | 179 | 218 | 279 | 289 | 180 | 599 | 374 | 380 | 249 | 435 | 378 | 320 | 234 | 291 | 296 | 247 | 217 | 353 | 360 | 422 | 204 | 413 | 468 | 483 |
| Operating Profit % | 14 % | 17 % | 23 % | 19 % | 18 % | 21 % | 22 % | 15 % | 38 % | 26 % | 26 % | 21 % | 26 % | 23 % | 22 % | 17 % | 17 % | 16 % | 14 % | 12 % | 19 % | 16 % | 16 % | 9 % | 19 % | 19 % | 21 % |
| Depreciation | 47 | 45 | 46 | 45 | 46 | 50 | 51 | 64 | 51 | 52 | 54 | 53 | 56 | 57 | 59 | 61 | 62 | 64 | 67 | 70 | 69 | 90 | 100 | 98 | 99 | 100 | 99 |
| Interest | 5 | 2 | 5 | 6 | 5 | 4 | 4 | 4 | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 3 | 7 | 9 | 11 | 19 | 31 | 44 | 33 | 29 | 24 | 23 | 17 |
| Profit Before Tax | 82 | 141 | 197 | 128 | 167 | 225 | 234 | 112 | 546 | 319 | 324 | 195 | 377 | 320 | 260 | 170 | 223 | 223 | 169 | 129 | 252 | 225 | 289 | 77 | 290 | 345 | 368 |
| Tax | 13 | 22 | 37 | 32 | 37 | 32 | 37 | 29 | 100 | 53 | 57 | 33 | 71 | 68 | 62 | 38 | 78 | 77 | 60 | 51 | 88 | 89 | 68 | 75 | 91 | 99 | 92 |
| Net Profit | 69 | 119 | 159 | 96 | 129 | 194 | 198 | 83 | 446 | 267 | 268 | 161 | 307 | 252 | 198 | 132 | 145 | 146 | 110 | 78 | 164 | 137 | 221 | 1 | 199 | 246 | 276 |
| EPS in ₹ | 5.43 | 9.38 | 12.59 | 7.60 | 10.24 | 15.32 | 15.63 | 6.57 | 35.27 | 21.11 | 21.09 | 12.71 | 24.18 | 19.73 | 7.76 | 5.13 | 5.64 | 5.67 | 4.25 | 3.02 | 6.42 | 5.72 | 7.09 | 2.35 | 7.58 | 9.05 | 9.78 |
IPCA Laboratories
1,330.95
+36.10
(2.79%)
Market Cap
33,766.76 Cr
EPS
21.57
PE Ratio
41.49
Dividend Yield
0.31 %
Industry
Healthcare52 Week High
1,755.90
52 Week Low
1,052.00
PB Ratio
4.91
Debt to Equity
0.24
Sector
Pharmaceuticals
Investment Returns
In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from13 analysts
Peer Comparison Compare Peers on Screener
| Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,687.55 | #1 4,04,899.77 | 33.61 | #1 49,887.20 | 12.06 | #1 9,648 | 13.77 | 47.60 | |
5,589.30 | 1,48,378.35 | 69.15 | 8,184.00 | 0.89 | 1,600 | #1 64.53 | 47.92 | |
1,463.05 | 1,18,158.10 | 22.92 | 26,520.70 | 14.17 | 4,155 | 47.38 | 50.89 | |
3,129.00 | 1,05,899.58 | 56.83 | 10,785.70 | 11.59 | 1,656 | 13.54 | 45.29 | |
2,350.50 | 96,976.58 | 46.77 | 10,615.60 | 19.57 | 1,942 | -16.38 | 48.68 | |
1,109.50 | 92,582.82 | #1 17.01 | 28,905.40 | 12.36 | 5,578 | 1.69 | 40.66 | |
1,969.25 | 89,904.33 | 30.58 | 20,141.50 | #1 19.94 | 1,936 | 38.82 | 46.62 | |
868.85 | 87,426.64 | 18.74 | 19,831.50 | 13.82 | 3,831 | 29.92 | 44.56 | |
29,641.10 | 62,985.27 | 46.40 | 6,097.20 | 10.80 | 1,201 | 16.01 | 48.36 | |
1,082.45 | 62,868.87 | 17.41 | 29,559.20 | 17.55 | 3,169 | -10.04 | 41.61 |
Automatic Screeners on ScanX
Growth Rate
Revenue Growth
22.92 %
Net Income Growth
7.58 %
Cash Flow Change
17.23 %
ROE
-17.67 %
ROCE
-3.19 %
EBITDA Margin (Avg.)
11.80 %
Quarterly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Total Assets | 3,812 | 3,892 | 3,960 | 4,117 | 4,551 | 5,260 | 6,068 | 7,624 | 8,626 | 11,101 |
| Fixed Assets | 1,800 | 2,014 | 1,983 | 1,953 | 1,940 | 2,059 | 2,072 | 2,402 | 2,751 | 4,553 |
| Current Assets | 1,614 | 1,622 | 1,742 | 1,946 | 2,378 | 2,856 | 3,437 | 4,447 | 5,189 | 5,539 |
| Capital Work in Progress | 267 | 129 | 95 | 73 | 66 | 133 | 235 | 306 | 140 | 343 |
| Investments | 0 | 26 | 136 | 87 | 120 | 310 | 505 | 989 | 626 | 862 |
| Other Assets | 1,745 | 1,723 | 1,746 | 2,005 | 2,424 | 2,758 | 3,256 | 3,926 | 5,109 | 5,343 |
| Total Liabilities | 3,812 | 3,892 | 3,960 | 4,117 | 4,551 | 5,260 | 6,068 | 7,624 | 8,626 | 11,101 |
| Current Liabilities | 904 | 970 | 956 | 1,008 | 1,098 | 1,326 | 1,161 | 1,466 | 1,806 | 2,356 |
| Non Current Liabilities | 700 | 663 | 548 | 421 | 315 | 292 | 192 | 616 | 905 | 1,019 |
| Total Equity | 2,208 | 2,259 | 2,455 | 2,689 | 3,138 | 3,641 | 4,716 | 5,542 | 5,915 | 7,727 |
| Reserve & Surplus | 2,183 | 2,234 | 2,430 | 2,663 | 3,097 | 3,590 | 4,676 | 5,440 | 5,817 | 6,307 |
| Share Capital | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 | 25 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
| Net Cash Flow | 29 | 29 | -26 | 75 | 153 | -76 | 264 | 432 | 588 | -823 |
| Investing Activities | -689 | -218 | -149 | -135 | -165 | -509 | -521 | -851 | -725 | -1,215 |
| Operating Activities | 468 | 709 | 282 | 341 | 501 | 570 | 1,090 | 856 | 806 | 945 |
| Financing Activities | 251 | -462 | -159 | -130 | -183 | -137 | -306 | 427 | 507 | -553 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Mar 2025 |
| Promoter | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.29 % | 46.30 % | 46.30 % | 46.30 % | 44.72 % | 44.72 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.02 % | 0.02 % | 0.02 % | 0.00 % | 9.86 % | 0.00 % | 10.51 % | 10.85 % | 10.83 % | 11.07 % | 10.76 % |
| DIIs | 24.49 % | 24.86 % | 25.00 % | 29.73 % | 32.41 % | 33.31 % | 33.29 % | 34.03 % | 33.55 % | 35.19 % | 35.05 % | 33.79 % | 34.37 % | 33.78 % | 34.23 % | 35.68 % | 36.06 % |
| Government | 0.28 % | 0.22 % | 0.22 % | 0.24 % | 0.24 % | 0.24 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 8.74 % | 8.25 % | 7.61 % | 7.75 % | 7.79 % | 7.50 % | 7.44 % | 7.41 % | 7.26 % | 6.98 % | 7.14 % | 7.12 % | 7.13 % | 7.27 % | 6.93 % | 6.88 % | 6.81 % |
| Others | 20.20 % | 20.39 % | 20.89 % | 15.99 % | 13.27 % | 12.66 % | 12.97 % | 12.26 % | 12.89 % | 11.54 % | 1.67 % | 12.80 % | 1.69 % | 1.79 % | 1.71 % | 1.65 % | 1.65 % |
| No of Share Holders | 1,00,626 | 1,05,428 | 95,239 | 1,06,779 | 1,15,335 | 1,10,818 | 1,11,043 | 1,08,177 | 1,10,296 | 99,889 | 95,930 | 82,809 | 81,165 | 84,753 | 82,975 | 90,189 | 88,306 |
Dividend History
Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 1 | 1 | 3 | 5 | 8 | 4 | 4 | 4 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.31 | 0.2 | 0.43 | 0.53 | 0.75 | 0.51 | 0.32 | 0.27 | 0.00 |
Corporate Action
Login to View
This information is available only for users of ScanX and Dhan.To proceed ahead,
LoginOpen Account
Announcements
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
7 days ago
7 days agoSlump Sale Of Manufacturing Unit And AcquisitionMar 28, 2025
Mar 28, 2025Announcement under Regulation 30 (LODR)-AcquisitionMar 28, 2025
Mar 28, 2025Board Meeting Outcome for Outcome Of Board MeetingMar 28, 2025
Mar 28, 2025Closure of Trading WindowMar 26, 2025
Mar 26, 2025Announcement under Regulation 30 (LODR)-Change in ManagementMar 03, 2025
Mar 03, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 14, 2025
Feb 14, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeFeb 13, 2025
Feb 13, 2025Integrated Filing (Financial)Feb 13, 2025
Feb 13, 2025Standalone And Consolidated Q3FY25 ResultsFeb 13, 2025
Feb 13, 2025Board Meeting Outcome for Standalone And Consolidated Q3FY25 Results & Press ReleaseFeb 13, 2025
Feb 13, 2025Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationFeb 10, 2025
Feb 10, 2025Order Received Under CGST ActFeb 07, 2025
Feb 07, 2025Order Received Under Central Goods And Service Tax Act 2017Feb 05, 2025
Feb 05, 2025Orders Received Under CGST ActJan 29, 2025
Jan 29, 2025Board Meeting Intimation for Standalone And Consolidated Unaudited Financial Results For Q3 And Nine Months Ended 31St December 2024Jan 27, 2025
Jan 27, 2025Order Received From Assistant Commissioner CGST RatlamJan 16, 2025
Jan 16, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 08, 2025
Jan 08, 2025Change Of Name Of Registrar And Share Transfer Agent ("RTA") Of The CompanyJan 03, 2025
Jan 03, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Dec 23, 2024
Dec 23, 2024Voluntary Closure Of The Company''s Wholly Owned Subsidiary Ipca Pharmaceuticals Ltd SA De CV, MexicoDec 04, 2024
Dec 04, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 22, 2024
Nov 22, 2024Revision In Record Date For Entitlement Of Interim DividendNov 18, 2024
Nov 18, 2024Revision In Record Date For Entitlement Of Interim DividendNov 18, 2024
Nov 18, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 18, 2024
Nov 18, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 15, 2024
Nov 15, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - OutcomeNov 14, 2024
Nov 14, 2024Corporate Action-Board approves DividendNov 14, 2024
Nov 14, 2024Unaudited Standalone And Consolidated Financial Results For Q2H1FY25Nov 14, 2024
Nov 14, 2024Board Meeting Outcome for Unaudited Standalone And Consolidated Financial Results For Q2H1FY25Nov 14, 2024
Nov 14, 2024Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - IntimationNov 08, 2024
Nov 08, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationOct 30, 2024
Oct 30, 2024Revision In Record Date For Entitlement Of Interim DividendOct 28, 2024
Oct 28, 2024Revision In Record Date For Interim DividendOct 28, 2024
Oct 28, 2024Corporate Action-Board to consider DividendOct 24, 2024
Oct 24, 2024Record Date For DividendOct 24, 2024
Oct 24, 2024Board Meeting Intimation for Standalone And Consolidated Financial Results For 2Nd Quarter And Half Year Ended 30Th September, 2024 And Declaration Of Interim DividendOct 24, 2024
Oct 24, 2024Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018Oct 08, 2024
Oct 08, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateOct 04, 2024
Oct 04, 2024To Enter Into Agreements By Bayshore Pharmaceuticals LLC, USA With Unichem Laboratories Limited And UnichemPharmaceuticals (USA) Inc So As To Integrate And Consolidate All The Ipca Group'S USA Generic Formulations Business Under One EntitySep 30, 2024
Sep 30, 2024Board Meeting Outcome for To Enter Into Agreements By Bayshore Pharmaceuticals LLC, USA With Unichem Laboratories Limited And Unichem Pharmaceuticals (USA) Inc So As To Integrate And Consolidate All The Ipca Group'S USA Generic Formulations Business Under One EntitySep 30, 2024
Sep 30, 2024Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 27, 2024
Sep 27, 2024Board Meeting Intimation for Integration And Consolidation Of The Generics Formulations Business In The US MarketSep 23, 2024
Sep 23, 2024Closure of Trading WindowSep 23, 2024
Sep 23, 2024Announcement under Regulation 30 (LODR)-Change in DirectorateSep 20, 2024
Sep 20, 2024Order Received From The Joint Commissioner (Appeals), CGST Jaipur Under Section 107 Of The CGST Act, 2017Sep 20, 2024
Sep 20, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 18, 2024
Sep 18, 2024Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011Sep 06, 2024
Sep 06, 2024Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateSep 02, 2024
Sep 02, 2024Technical Indicators
RSI(14)
Neutral 44.66
ATR(14)
Less Volatile 78.29
STOCH(9,6)
Neutral 48.26
STOCH RSI(14)
Oversold 15.48
MACD(12,26)
Bearish -9.83
ADX(14)
Weak Trend 22.37
UO(9)
Bearish 54.79
ROC(12)
Downtrend And Accelerating -8.40
WillR(14)
Neutral -53.09
About IPCA Laboratories
Ipca Laboratories Limited is an Indian integrated pharmaceutical company that manufactures and markets over 350 formulations and 80 active pharmaceutical ingredients (APIs) across various therapeutic segments. The company operates 18 manufacturing units in India and sells its products in over 100 countries worldwide. Ipca specializes in producing APIs such as Atenolol, Chloroquine Phosphate, Furosemide, and Pyrantel Salts. The company's facilities are approved by major drug regulatory authorities including the US FDA, UK MHRA, and others. Ipca has expanded through acquisitions and joint ventures, and has subsidiaries in various countries. The company focuses on research and development, and has recently acquired stakes in other pharmaceutical companies to strengthen its market position.
Website
Chairperson NamePremchand Godha
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
